The Measles-Containing-Vaccine Second-Dose (MCV2) immunization coverage in the US is forecasted to remain steady at 95% from 2024 to 2028. Compared to 2023, where the actual coverage was also 95%, there is no year-on-year variation, indicating stability without significant growth or decline. There’s no noted change in the average annual growth rate (CAGR) over the last five years as the figures represent a plateau in coverage rates.
Future trends to watch for:
- Monitoring potential policy changes that might influence vaccine coverage rates.
- Evaluating impacts of public health campaigns and vaccine access initiatives.
- Assessing effects of emerging health threats on immunization rates.
